Abiopharma

🔍 Lee James CI (Executive)

Company: Seagate Technology Holdings plc (STX)

Report Date: 2026-04-22

Detailed Transactions and Holdings:

• Acquired 1,237 shares of Ordinary Shares (Direct)
  Date: 2026-04-22 | Code: M | equity_swap_involved: 0 | shares_owned_after: 1,561.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 540 shares of Ordinary Shares at $579.88 per share (Direct)
  Date: 2026-04-22 | Code: F | equity_swap_involved: 0 | shares_owned_after: 1,021.00 | transaction_form_type: 4
• Sold 1,237 shares of Restricted Share Unit (Derivative)
  Date: 2026-04-22 | Code: M | equity_swap_involved: 0 | shares_owned_after: 11,139.00 | transaction_form_type: 4 | Footnotes: F2, F3, F3

Footnotes:

• F1: Includes 67 Ordinary Shares purchased by Reporting Person on January 31, 2026 under the Issuer's Employee Stock Purchase Plan. Such acquisition is exempt from reporting pursuant to Rule 16b-3 under the Securities Exchange Act of 1934.
• F2: Each restricted share unit ("RSU") represents a contingent right to receive one Ordinary Share of the Issuer.
• F3: Consists of a grant of RSUs awarded to the Reporting Person under the Seagate Technology Holdings plc 2022 Equity Incentive Plan. Such RSUs vested as to one-quarter of the shares on July 22, 2025 and then in equal quarterly installments thereafter.